

21 June 2010

ASX Limited  
Adviser, Issuers (Sydney)  
Exchange Centre  
20 Bridge Street  
Sydney NSW 2000

Attention: Emma Badhni

Dear Ms Badhni,


### **Request for Trading Halt**

Pharmaxis Ltd (**Pharmaxis**) requests an immediate trading halt of its securities pending the announcement of results from its second international Phase III trial of Bronchitol<sup>®</sup> in patients with cystic fibrosis.

Pharmaxis requests that the trading halt continue until the commencement of trading on 23 June 2010. Pharmaxis will make another announcement in connection with the clinical trial prior to the end of the trading halt.

In accordance with ASX Listing Rule 17.1, Pharmaxis confirms that it is not aware of any reason why the trading halt should not be granted.

Yours sincerely,



David McGarvey  
Chief Financial Officer/ Company Secretary